An investigation designed an oncolytic adenovirus expressing BiTE targeting EGFR in combination with anti‐FR‐α CAR‐T cells.[175] This study demonstrated that combination therapy promotes CAR‐T cell proliferation, activation, and tumor cell killing ability and activation. This evidence concerns the gene EGFR and neoplasm.